Quantitative structure-activity relationship of multidrug resistance reversal agents

Molecular Pharmacology

Volumn 52, Issue 2, 1997, Pages 323-334

  Klopman, Gilles ^a   Shi, Leming M ^a   Ramu, Avner ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CEPHALOSPORIN DERIVATIVE; COLCHICINE; CYCLOPEPTIDE; DACTINOMYCIN; DAUNORUBICIN; DIHYDROPYRIDINE DERIVATIVE; DIPYRIDAMOLE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL DERIVATIVE; PHENOTHIAZINE DERIVATIVE; RESERPINE; TENIPOSIDE; THIOXANTHENE DERIVATIVE; TRIAZINE DERIVATIVE; VERAPAMIL; VINBLASTINE; VINCRISTINE; YOHIMBINE;

ARTICLE; CANCER CHEMOTHERAPY; COMPUTER PROGRAM; DRUG ACTIVITY; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0030800078     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.2.323     Document Type: Article

References (54)

1. Pratt, W. B., R. W. Ruddon, W. D. Ensminger, and J. Maybaum. The Anticancer Drugs. Oxford University Press, Oxford (1994).
2. Biedler, J. L., and H. Riehm. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30:1174-1184 (1970).
3. Ford, J. M. Modulators of multidrug resistance - preclinical studies. Hematol. Oncol. Clin. N. Am. 9:337-361 (1995).
4. Nielsen, D., and T. Skovsgaard. P-glycoprotein as a multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim. Biophy. Acta 1139:169-183 (1992).
5. Juliano, R. L., and V. Ling. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophy. Acta 455:152-162 (1976).
6. Riordan, J. R., and V. Ling. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J. Biol. Chem. 254:12701-12705 (1979).
7. Chen, C.-j., J. E. Chin, K. Ueda, D. P. Clark, I. Pastan, M. M. Gottesman, and I. B. Roninson. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389 (1986).
8. Gottesman, M. M., and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427 (1993).
9. List, A. F. Multidrug Resistance: clinical relevance in acute leukemia. Oncology 7:23-28, 32, 35-38 (1993).
10. Zamora, J. M., H. L. Pearce, and W. T. Beck. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:454-462 (1988).
11. Ramu, A., and N. Ramu. Resistance to lipophilic cationic compounds in multidrug resistant leukemia cells. Leuk. Lymphoma 9:247-253 (1993).
12. Mickisch, G. H., G. T. Merlino, P. M. Aiken, M. M. Gottesman, and I. Pastan. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDRl gene. J. Urol. 146:447-453 (1991).
13. Yang, J. M., S. Goldenberg, M. M. Gottesman, and W. N. Hait. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 54:730-737 (1994).
14. Lehnert, M. Reversal of P-glycoprotein-associated multidrug resistance: the challenge continues. Eur. J. Cancer 29A:636-638 (1993).
15. Fisher, G. A., and B. I. Sikic. Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. N. Am. 9:363-382 (1995).
16. Dalton, W. S., J. J. Crowley, S. S. Salmon, T. M. Grogan, L. R. Laufman, G. R. Weiss, and J. D. Bonnet. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest oncology group study. Cancer (Phila.) 75:815-820 (1995).
17. Hait, W. N., and D. T. Aftab. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem. Pharmacol. 43:103-107 (1992).
18. Priebe, W., and R. Perez-Soler. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol Ther. 60:215-234 (1993).
19. Lee, J. S., K. Paull, M. Alvarez, C. Hose, A. Monks, M. Grever, A. T. Fojo, and S. E. Bates. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46:627-638 (1994).
20. Paull, K. D., R. H. Shoemaker, L. Hodes, A. Monks, D. A. Scudiero, L. Rubinstein, J. Plowman, and M. R. Boyd. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 81:1088-1092 (1989).
21. Dellinger, M., B. C. Pressman, C. Calderon-Higginson, N. Savaraj, H. Tapiero, D. Kolonias, and T. J. Lampidis. Structural requirements of simple organic cations for recognition by multidrug resistant cells. Cancer Res. 52:6385-6389 (1992).
22. Wadkins, R. M., and P. J. Houghton. The role of drug-lipid interactions in the biological activity of modulators of multi-drug resistance. Biochim. Biophys. Acta 1153:225-236 (1993).
23. Simon, S. M., and M. Schindler. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA 91:3497-3504 (1994).
24. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science (Washington D. C.) 257:1078-1082 (1992).
25. Klopman, G. MULTICASE. A hierarchical computer automated structure evaluation program. Quant. Struct.-Act. Relat. 11:176-184 (1992).
26. Klopman, G., S. Srivastava, I. Kolossvary, R. F. Epand, N. Ahmed, and R. M. Epand. Structure-activity study, and design of multidrug-resistant reversal compounds by a computer automated structure evaluation methodology. Cancer Res. 52:4121-4129 (1992).
27. Ramu, A., and N. Ramu. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother. Pharmacol. 30:165-173 (1992).
28. Ramu, A., and N. Ramu. Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds. Cancer Chemother. Pharmacol. 34:423-430 (1994).
29. Devine, S. E., and P. Melera. Diversity of multidrug resistance in mammalian cells. J. Biol. Chem. 269:6133-6139 (1994).
30. Tew, K. D., P. J. Houghton, and J. A. Houghton. Chapter 5. Modulation of P-glycoprotein-mediated multidrug resistance, in Preclinical and Clinical Modulation of Anticancer Drugs. CRC Press, Boca Raton, FL, 125-196 (1993).
31. Huet, S., C. Chapey, and J. Robert. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur. J. Cancer 29A:1377-1383 (1993).
32. Ramu, N., and A. Ramu. Circumvention of adriamycin resistance by dipyridamole analogues: a structure-activity relationship study. Intl. J. Cancer 43:487-491 (1989).
33. Klopman, G., and M. McGonigal. Computer simulation of physical chemical properties of organic molecules. J. Chem. Inf. Comput. Sci. 21:48-52 (1981).
34. Klopman, G. Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules. J. Am. Chem. Soc. 106:7315-7320 (1984).
35. Burley, S. K., and G. A. Petsko. Weakly polar interactions in proteins. Adv. Protein Chem. 39:125-189 (1988).
36. Pawagi, A. B., J. Wang, M. Silverman, R. A. F. Reithmeier, and C. M. Deber. Transmembrane aromatic amino acid distribution in P-glycoprotein: a functional role in broad substrate specificity. J. Mol. Biol. 235:554-564 (1994).
37. Georg, G. I., T. T. Chen, I. Ojima, and D. M. Vyas. Taxane anticancer agents. Basic science and current status. ACS Symp. Ser. 583:1-353 (1995).
38. Fruehauf, J. P., and A. Manetta. Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression. Contrib. Gynecol. Obstet. 19:39-52 (1994).
39. Lehnert, M., S. Emerson, W. S. Dalton, R. de Giuli, and S. E. Salmon. In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. Monogr. Natl. Cancer Inst. 15:63-67 (1993).
40. Tang-Wai, D. F., A. Brossi, L. D. Arnold, and P. Gros. The nitrogen of the acetamido group of colchicine modulates P-glycoprotein-mediated multidrug resistance. Biochemistry 32:6470-6476 (1993).
41. Pearce, H. L., A. L. Safa, N. J. Bach, M. A. Winter, M. C. Cirtain, and W. T. Beck. Essential features of the P-glycoprotein pharmacophore as denned by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl. Acad. Sci. USA 86:5128-5132 (1989).
42. Pearce, H. L., M. A. Winter, and W. T. Beck. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv. Enzyme Regul. 30:357-373 (1990).
43. Inaba, M., and E. Maruyama. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine. Cancer Res. 48:2064-2067 (1988).
44. Hofsli, E., and J. Nissen-Meyer. Reversal of multidrug resistance by lipophilic drugs. Cancer Res. 50:3997-4002 (1990).
45. Gosland, M. P., B. L. Lum, and B. I. Sikic. Reversal by Cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res. 49:6901-6905 (1989).
46. Nogae, I. K., Kohno, J. Kikuchi, M. Kuwano, S. Akiyama, A. Kiue, K. Suzuki, Y. Yoshida, M. M. Cornwell, I. Pastan, and M. M. Gottesman. Analysis of structural features of dihydropyride analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem. Pharmacol. 38:519-527 (1989).
47. 3H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydropyridine analogues in a human cell line. Cancer Res. 49:3190-3195 (1989).
48. Kiue, A., T. Sano, K. Suzuki, H. Inada, M. Okumura, J. Kikuchi, S. Sato, K. Kohno, and M. Kuwano. Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. Cancer Res. 50:310-317 (1990).
49. Ford, J. M., W. C. Prozialeck, and W. N. Hait. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 35:105-115 (1989).
50. Ford, J. M., E. P. Bruggemann, I. Pastan, M. M. Gottesman, and W. N. Hait. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 50: 1748-1756 (1990).
51. Thimmaiah, K. N., J. K. Horton, X. D. Qian, W. T. Beck, J. A. Houghton, and P. J. Houghton. Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines. Cancer Commun. 2:249-259 (1990).
52. Thimmaiah, K. N., J. K. Horton, E. Seshadri, M. Israel, J. A. Houghton, F. C. Harwood, and P. J. Houghton. Synthesis and chemical characterization of N-substituted phenoxazines directed toward reversing vinca alkaloid resistance in multidrug-resistant cancer cells. J. Med. Chem. 35:3358-3364 (1992).
53. Emmer, G., M. A. Grassberger, G. Schulz, D. Boesch, C. Gavenaux, and F. Loor. Derivatives of a novel cyclopeptide. 2. synthesis, activity against multidrug resistance in CHO and KB cells in vitro, and structure-activity relationships. J. Med. Chem. 37:1918-1928 (1994).
54. Dhainaut, A., G. Regnier, G. Atassi, A. Pierre, S. Leonce, L. Kraus-Berthier and J. F. Prost. New triazine derivatives as potent modulators of multidrug resistance. J. Med. Chem. 35:2481-2496 (1992).